HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Patrice Y Neese Selected Research

Vaccines

11/2014Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.
7/2010Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.
12/2008Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines.
10/2008Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
5/2008A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
11/2007Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
7/2005Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
3/2005MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
11/2004Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.
9/2004Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Patrice Y Neese Research Topics

Disease

9Melanoma (Melanoma, Malignant)
11/2014 - 11/2003
3Tetanus
07/2010 - 11/2003
3Neoplasms (Cancer)
07/2005 - 11/2003
2Injection Site Reaction
05/2008 - 09/2004
2Testicular Neoplasms (Testicular Cancer)
11/2007 - 03/2005
1Inflammation (Inflammations)
07/2010
1Experimental Melanoma
12/2008
1Carcinoma (Carcinomatosis)
05/2008
1Fatigue
05/2008
1Headache (Headaches)
05/2008
1Ovarian Neoplasms (Ovarian Cancer)
05/2008
1Autoimmune Thyroiditis (Lymphomatous Thyroiditis)
07/2005
1Anemia
09/2004
1Thrombocytosis (Thrombocythemia)
09/2004
1Vitiligo
11/2003

Drug/Important Bio-Agent (IBA)

11VaccinesIBA
11/2014 - 11/2003
8Peptides (Polypeptides)IBA
07/2010 - 11/2003
4Protein Subunit VaccinesIBA
11/2014 - 09/2004
4Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
07/2010 - 11/2003
3HLA-A2 Antigen (HLA A2 Antigen)IBA
05/2008 - 11/2003
3HLA Antigens (Human Leukocyte Antigens)IBA
05/2008 - 11/2004
3Proteins (Proteins, Gene)FDA Link
05/2008 - 03/2005
3HLA-A3 Antigen (HLA A3 Antigen)IBA
05/2008 - 11/2003
3Monatide (IMS 3015)IBA
07/2005 - 11/2003
3Interleukin-2 (IL2)IBA
07/2005 - 09/2004
2EpitopesIBA
11/2014 - 03/2005
2AntigensIBA
07/2010 - 11/2007
2Monophenol Monooxygenase (Tyrosinase)IBA
11/2004 - 11/2003
1incomplete Freund's adjuvantIBA
07/2010
1Differentiation AntigensIBA
10/2008
1Tetanus Toxoid (Vaccine, Tetanus)FDA Link
05/2008
1AutoantigensIBA
07/2005
1AntibodiesIBA
07/2005
1gp100(280-288) melanoma antigen peptideIBA
11/2004
1gp100(17-25) peptideIBA
11/2004
1EmulsionsIBA
11/2003
1HLA-A1 Antigen (HLA A1 Antigen)IBA
11/2003

Therapy/Procedure

2Therapeutics
11/2014 - 09/2004
1Immunomodulation
05/2008
1Immunotherapy
07/2005